Pfizer mode being questioned

Today, well-known pharmaceutical analyst Bernard Munos questioned Pfizer rely on acquisitions to sustain growth of the business model in Forbes's column. Although repeated acquisitions greatly increase sales, but the net profit increase is limited. Pfizer, the market value of 120 billion in 2000, and now 200 billion, and McDonald's burger price growth rate almost. While shareholders get $ 95 billion in dividends, but Pfizer stock is now lower than in 1999 (of course, when there is a bubble biopharmaceuticals). He believes that patients decrease the use of innovative drugs is the main pressure of the whole industry growth, of course, are the same for all pharmaceutical companies. The key to survival is to improve the patient's unit profit, but price increases have been limited by space. He said Pfizer has talent, courage, have the resources, do not need to transfer the headquarters of such means of tax avoidance